Tag Archives: Safety Communication

Methylphenidate ADHD Medications Drug Safety Communication

Share

translation servicesTranslate | French translation Spanish translation translate German translate Chinese Methylphenidate ADHD Medications: Drug Safety Communication – Risk of Long-lasting Erections Including Concerta, Daytrana, Focalin/Focalin XR, Metadate CD/Metadate ER, Methylin/Methylin ER, Quillivant XR, Ritalin/Ritalin LA/Ritalin SR AUDIENCE: Psychiatry, Family … Continue reading

Share
Posted in Consumer Products, Family Practice, FDA 2013, FDA Warning, Psychiatry | Tagged , , , , , , , , , , , , , , , , , | Comments Off on Methylphenidate ADHD Medications Drug Safety Communication

HeartStart Automated External Defibrillators AED Philips Healthcare

Share

translation servicesTranslate | French translation Spanish translation translate German translate ChineseHeartStart Automated External Defibrillators (AED) From Philips Healthcare: Safety Communication – Failure Of An Electrical Component That Could Cause AEDs To Fail To Deliver Appropriate Shock AUDIENCE: Risk Manager, Emergency … Continue reading

Share
Posted in Emergency Medicine, FDA 2013, FDA Safety Communication, Healthcare Professionals, Risk Manager | Tagged , , , , , , , , , , | Comments Off on HeartStart Automated External Defibrillators AED Philips Healthcare

Lexiscan regadenoson and Adenoscan adenosine Drug Safety Communication

Share

translation servicesTranslate | French translation Spanish translation translate German translate ChineseLexiscan (regadenoson) and Adenoscan (adenosine): Drug Safety Communication – Rare but Serious Risk of Heart Attack and Death AUDIENCE: Cardiology, Pharmacy, Radiology ISSUE: The FDA is warning health care professionals … Continue reading

Share
Posted in Cardiology, FDA 2013, FDA Safety Communication, Pharmacy, Radiology | Tagged , , , , , , , , , , , | Comments Off on Lexiscan regadenoson and Adenoscan adenosine Drug Safety Communication

MedWatch October 2013 Safety Labeling Changes

Share

translation servicesTranslate | French translation Spanish translation translate German translate ChineseThe MedWatch October 2013 Safety Labeling Changes posting includes 68 products with safety labeling changes to the following sections: BOXED WARNINGS, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS and PATIENT PACKAGE INSERT. … Continue reading

Share
Posted in FDA 2013, FDA Label Change, FDA Safety Communication | Tagged , , , , , , , , | Comments Off on MedWatch October 2013 Safety Labeling Changes

Over the Counter Topical Antiseptic Products Drug Safety Communication

Share

translation servicesTranslate | French translation Spanish translation translate German translate ChineseOver-the-Counter Topical Antiseptic Products: Drug Safety Communication – FDA Requests Label Changes and Single-Use Packaging to Decrease Risk of Infection AUDIENCE: Healthcare Professional, Risk Manager, Pharmacy ISSUE: The U.S. Food … Continue reading

Share
Posted in FDA 2013, FDA Label Change, Healthcare Professionals, Pharmacy, Risk Manager | Tagged , , , , , , , , , | Comments Off on Over the Counter Topical Antiseptic Products Drug Safety Communication

Low Molecular Weight Heparins Drug Safety Communication

Share

translation servicesTranslate | French translation Spanish translation translate German translate ChineseLow Molecular Weight Heparins: Drug Safety Communication – Recommendations to Decrease Risk of Spinal Column Bleeding and Paralysis AUDIENCE: Pharmacy, Cardiology, Anesthesiology ISSUE: The U.S. Food and Drug Administration (FDA) … Continue reading

Share
Posted in Anesthesiology, Cardiology, FDA 2013, FDA Safety Communication, Pharmacy | Tagged , , , , , , , , , | Comments Off on Low Molecular Weight Heparins Drug Safety Communication

MedWatch September 2013 Safety Labeling Changes

Share

translation servicesTranslate | French translation Spanish translation translate German translate ChineseThe MedWatch September 2013 Safety Labeling Changes posting includes 49 products with safety labeling changes to the following sections: BOXED WARNINGS, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS and PATIENT PACKAGE INSERT. The … Continue reading

Share
Posted in FDA 2013, FDA Label Change | Tagged , , , , , , , | Comments Off on MedWatch September 2013 Safety Labeling Changes

St Jude Amplatzer Atrial Septal Occluder ASO Safety Communication

Share

translation servicesTranslate | French translation Spanish translation translate German translate ChineseSt. Jude Amplatzer Atrial Septal Occluder (ASO): Safety Communication – Reports of Tissue Erosion AUDIENCE: Cardiology, Risk Manager, Patient ISSUE: FDA is alerting health care providers and patients that in … Continue reading

Share
Posted in Cardiology, FDA 2013, FDA Notice, FDA Safety Communication, Patients, Risk Manager | Tagged , , , , , , , , , , , | Comments Off on St Jude Amplatzer Atrial Septal Occluder ASO Safety Communication

Inclusig Ponatinib Drug Safety Communication

Share

translation servicesTranslate | French translation Spanish translation translate German translate ChineseInclusig (Ponatinib): Drug Safety Communication – Increased Reports Of Serious Blood Clots In Arteries And Veins AUDIENCE: Health Professional, Oncology ISSUE: FDA is investigating an increasing frequency of reports of … Continue reading

Share
Posted in FDA 2013, FDA Safety Communication, Healthcare Professionals, Oncology | Tagged , , , , , , , , | Comments Off on Inclusig Ponatinib Drug Safety Communication

Tygacil tigecycline Drug Safety Communication

Share

translation servicesTranslate | French translation Spanish translation translate German translate ChineseTygacil (tigecycline): Drug Safety Communication – Increased Risk of Death AUDIENCE: Infectious Disease, Critical Care, Pharmacy ISSUE: FDA notified health professionals and their medical care organizations of a new Boxed … Continue reading

Share
Posted in Critical Care Medicine, FDA 2013, FDA Safety Communication, Infectious Disease, Pharmacy | Tagged , , , , , , , , , | Comments Off on Tygacil tigecycline Drug Safety Communication